Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin

Early Phase 1

Completed

• Conditions: Venous Thromboembolism; Deep Vein Thrombosis; Pulmonary Embolism
• Interventions: Drug: Standard heparin dose; Drug: Real time heparin dose adjustment

• Registration Number: NCT03516656
• Lead Sponsor: University of Utah

Brief Summary

The purpose of this study is to determine if weight-based heparin infusions at a rate of 10 units/kg/hour are sufficient to maintain a target anti-Xa of 0.1-0.35 IU/mL for VTE prophylaxis in patients undergoing microvascular surgery. Additionally, a pilot protocol has been developed to titrate these heparin infusions to ensure patients have sufficient VTE prophylaxis. All patients will be enrolled in the observational arm of the study and receive anti-Xa level monitoring. Patients with out-of-range anti-Xa levels will cross over to the interventional arm of the study and receive real time heparin infusion dose adjustments per the pilot protocol. The primary outcome measured will be the percentage of patients with anti-Xa levels in the target range of 0.1-0.35 IU/mL while on a heparin infusion at 10 units/kg/hour.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-03-23
• Study First Submitted: 2018-04-24
• Study First Submitted QC: 2018-04-24
• Study First Posted: 2018-05-04
• Primary Completion: 2019-06-30
• Status Verified: 2020-11
• Study Completion: 2021-08-24
• Last Update Submitted: 2023-05-15
• Last Update Posted: 2023-05-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Patients undergoing surgical procedures
• Initiation of a heparin infusion at a rate of 500 units/hour intraoperatively or postoperatively

Read More

Exclusion Criteria

• Age <18 years old
• Pregnant
• Incarcerated
• Mentally disabled

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Standard heparin dose	Standard heparin dose	The investigators will identify surgical patients placed on fixed dose heparin infusions at their attending surgeon's discretion-the proposed research will not dictate the initiation of the heparin drip intraoperatively. However, the investigators will identify patients already on heparin, evaluate steady state heparin anti-Xa levels and adjust patient's dose if necessary based on steady state anti-Xa levels. Eligible patients will be started on heparin fixed-dose intraoperatively and transitioned to a weight-based dose by their surgeons. Steady state anti-Xa levels will be drawn at least 6 hours after initiation of heparin infusion. Goal anti-Xa levels will be 0.1-0.35 IU/mL.
Real time heparin dose adjustment	Real time heparin dose adjustment	Patients with identified out of range levels will receive pharmacist-driven real time heparin dose adjustment and will receive follow-up steady state anti-Xa levels. Anti-Xa level monitoring will be discontinued when in range peak levels are obtained, when heparin infusions are discontinued at surgeon discretion, or when the patient is discharged

Primary Outcome Measures

Name	Time	Method
Percentage of Anti-Xa Levels Within Target Range (0.1-0.35 IU/mL)	Through study completion, an average of 1 year

Secondary Outcome Measures

Name	Time	Method
Number of Rate Adjustments	Through study completion, an average of 1 year

Trial Locations

Locations (1)

University of Utah; 🇺🇸 Salt Lake City, Utah, United States